Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

See Remarks

Senior VP, R&D

Chief Operating Officer

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process i...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-06-14	Premium	bought	Premium	Premium	Premium	-
2024-06-14	Premium	bought	Premium	Premium	Premium	-
2024-06-14	Premium	acquired	Premium	Premium	Premium	-
2024-06-14	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2024-05-21	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-16	Premium	acquired	Premium	Premium	Premium	-
2024-05-14	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-05-14	Premium	sold (taxes)	Premium	Premium	Premium	Senior VP, R&D

RGEN - Repligen Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for RGEN